Indraprastha Medical Corporation shares surged 8.59% to ₹392.90 following robust first quarter FY27 results. The healthcare operator reported a net profit of ₹55.85 crore for Q1FY27, marking an 8.5% year-on-year increase from ₹51.46 crore in Q1FY26. Revenue from operations climbed to ₹406.15 crore, up 11.3% from ₹365.06 crore in Q1FY26, reflecting steady business growth and strong operational performance. The company's earnings per share increased to ₹6.09 from ₹5.61 in the corresponding prior period, demonstrating improved profitability despite margin compression pressures.
The company's total income increased 11.5% to ₹414.57 crore compared to ₹371.96 crore in Q1FY26, with other income rising 22.0% to ₹8.42 crore from ₹6.90 crore. However, total expenses grew 11.9% to ₹339.75 crore, slightly outpacing revenue growth, indicating margin compression pressure. Key cost drivers included professional charges to doctors, which increased 13.7% to ₹111.15 crore from ₹97.84 crore, while employee benefits expense rose 12.3% to ₹72.96 crore and cost of materials consumed grew 11.6% to ₹70.13 crore. Profit before tax climbed 9.5% to ₹74.82 crore, with tax expense recorded at ₹19.68 crore including a deferred tax credit of ₹0.71 crore.
In a board meeting held on August 6, 2026, the company's board approved September 18, 2026, as the record date to determine eligible shareholders for the dividend for FY2025-26 and participation in the upcoming Annual General Meeting. The board also approved convening the 38th Annual General Meeting (AGM), scheduled for September 24, 2026, which will be conducted via video conferencing or other audio-visual means. Additionally, the board re-appointed M/s Devarajan Swaminathan and Co., Cost Accountants, as Cost Auditors for the financial year 2026-27 based on the Audit Committee's recommendation.
The company currently commands a market capitalisation of approximately ₹3,317 crore, while its 52-week high stands at ₹640.85. From a technical perspective, Indraprastha Medical Corporation shares are showing signs of renewed strength with the Relative Strength Index (RSI) at 40, indicating the stock is neither in an overbought nor oversold zone. The stock is currently trading above 7 out of 8 key Simple Moving Averages (SMAs), suggesting a positive technical setup and improving momentum. Historical stock returns show +6.76% in 1 day, +7.37% in 5 days, +1.35% in 1 month, +2.06% in 6 months, and +373.12% over 1 year, demonstrating strong long-term performance despite recent volatility.
Foreign institutional investors (FIIs) have shown increased confidence in the company with their holding in Indraprastha Medical Corporation increasing to 2.77% in the June 2026 quarter from 2.43% in the previous quarter, indicating gradual institutional accumulation. This increased foreign investor participation, combined with strong quarterly growth and improving technical indicators, has helped the stock regain investor attention after a period of subdued performance. The company operates in a single segment—Healthcare—and has no subsidiaries, associates, or joint ventures as of June 30, 2026.
